SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending as rival Hims & Hers has halted its compounded weight-loss pill following legal action from NVO and increased FDA scrutiny on such alternatives, reinforcing NVO's market leadership. The community is actively discussing the implications of this development alongside Novo's promising oral Wegovy launch momentum and ongoing share buyback program.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community eagerly discusses the recent FDA approval of Bysanti for bipolar I disorder and schizophrenia, with many anticipating a significant valuation re-rating and potential for a short squeeze, especially given the drug's patent protection until 2044 and the broader 'mega blockbuster' potential of its pipeline.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid renewed uncertainty surrounding global trade policy, driven by recent tariff decisions that have sparked market volatility. The community is sharply divided, with bears anticipating a major downturn following weekend declines, while bulls expect a typical 'V-shape' recovery, particularly ahead of key tech earnings this week.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to its succession of record-breaking battery swaps, including hitting 1 million weekly swaps during the Chinese New Year holiday, which bulls highlight as proof of its BaaS ecosystem's strength and a precursor to anticipated profitability. However, the community remains divided, with skeptics dismissing holiday-inflated numbers and alleging continued stock manipulation, while broader discussions also focus on the potential impact of recent tariff rulings.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's recent CagriSema trial results fuel intense community speculation that VKTX's 'best-in-class' VK2735 obesity drug is now an even more attractive buyout or partnership target for major pharmaceutical companies like AbbVie, given its strong efficacy and tolerability in the rapidly expanding weight loss market.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending as investors await its earnings report and upcoming presentations of positive Navenibart trial data, a recently acquired long-acting HAE prophylactic. This is fueling community debate between optimism driven by institutional interest and persistent concerns over significant short positions.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending as investors eagerly anticipate its upcoming earnings report, driving significant community speculation around a potential buyout and a short squeeze due to high short interest. Discussions are also focused on recent partnership announcements and institutional buying, with many comparing its current valuation to peers in the insurtech sector.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is trending due to upcoming catalysts, including the FDA's PDUFA date in May 2026 for pediatric Afrezza and the recent launch of Afrezza in India, alongside its impending Q4 earnings report. The community is sharply divided between those anticipating significant growth from these developments and skeptics highlighting Afrezza's historical performance and expressing concerns over management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scotiabank Has Positive Forecast for DAR FY2026 Earnings

Darling Ingredients Inc. (NYSE:DAR - Free Report) - Equities research analysts at Scotiabank increased their FY2026 earnings estimates for Darling Ingredients in a report released on Thursday...

326,400 Shares in Darling Ingredients Inc. $DAR Purchased by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. bought a new position in Darling Ingredients Inc. (NYSE:DAR - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the...

Barings LLC Boosts Holdings in Darling Ingredients Inc. $DAR

Barings LLC raised its holdings in shares of Darling Ingredients Inc. (NYSE:DAR - Free Report) by 52.8% in the third quarter, according to the company in its most recent disclosure with the...

Bornite Capital Management LP Buys New Shares in Darling Ingredients Inc. $DAR

Bornite Capital Management LP purchased a new position in Darling Ingredients Inc. (NYSE:DAR - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm...

CenterBook Partners LP Raises Stock Position in Darling Ingredients Inc. $DAR

CenterBook Partners LP lifted its holdings in shares of Darling Ingredients Inc. (NYSE:DAR - Free Report) by 98.4% during the 3rd quarter, according to its most recent 13F filing with the Securities...

MidWestOne Financial Group Inc. Boosts Holdings in Darling Ingredients Inc. $DAR

MidWestOne Financial Group Inc. increased its position in Darling Ingredients Inc. (NYSE:DAR - Free Report) by 94.3% in the 3rd quarter, according to its most recent disclosure with the Securities...

TD Cowen Increases Darling Ingredients (NYSE:DAR) Price Target to $58.00

TD Cowen lifted their target price on Darling Ingredients from $45.00 to $58.00 and gave the company a "buy" rating in a research report on Friday...

Darling Ingredients Q4 Earnings Call Highlights

Darling Ingredients (NYSE:DAR) closed fiscal 2025 with fourth-quarter adjusted EBITDA of $336.1 million, supported by sequential gross margin improvement and stronger results in its core ingredients...

Darling Ingredients' Q4 Earnings and Sales Surpass Estimates

DAR tops earnings and sales estimates as revenues jump 20.6% and margins expand, driven by strong Feed and Food segment gains.

Darling (DAR) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Darling (DAR) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Darling Ingredients, Inc. engages in the development and production of natural ingredients from edible and inedible bio-nutrients. It operates through the following segments: Feed Ingredients, Food Ingredients, and Fuel Ingredients. The Feed Ingredients segment includes ingredients such as fats and proteins used cooking oil, trap grease and food residuals collection, the Rothsay ingredients, and specialty products. The Food Ingredients segment consists of gelatin, natural casings and meat by-products, and specialty products activities. The Fuel Ingredients segment includes the bioenergy business. The company was founded in 1882 and is headquartered in Irving, TX.

Current Price	$51.60
Prev Close	$51.75
Open	$51.72
Dividend Yield	0.00%
50-Day Moving Average	$41.51
Beta	1.00
Avg. Volume	2.45M
PE Ratio	133.85

52-Week High	$52.88
52-Week Low	$26.00
Market Capitalization	$8.67B
EPS (Annual)	$0.39
Price to Book	1.74
Revenue Per Employee	$395,863.03

DAR
Darling Ingredients Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DAR News

DARDarling Ingredients Inc